Sexual Habits of Men with ED Who Take Phosphodiesterase 5 Inhibitors: a Survey Conducted in 7 Countries

Overview

Journal Int J Clin Pract

Publisher Wiley

Specialty General Medicine

Date 2018 Feb 21

PMID 29460994

Citations 4

Authors

John P Mulhall

Tarek A Hassan

James Rienow

Affiliations

Soon will be listed here.

Abstract

Introduction: Western cultural perceptions that favour spontaneous sex may create unrealistic expectations for erectile dysfunction (ED) treatment. Little is known about how users of phosphodiesterase type 5 inhibitors (PDE5Is) plan sexual activity and timing of their preactivity PDE5I ingestion. Because various PDE5Is vary in their duration of action and dosage regimen, this may be an important consideration in selecting the optimal agent for the ED patient.

Aim: To better understand the sexual habits of PDE5I users.

Methods: Men from 7 countries (Brazil, China, Italy, Japan, Russia, Taiwan, Turkey) were screened online for age, self-reported comorbidities and ED medication use in the prior 3 months. After screening, eligible participants were asked to complete a 7-question, self-administered online survey containing questions regarding sexual habits and behaviours.

Main Outcome Measures: Survey questions focused primarily on advanced planning of sexual intercourse and timing of PDE5I ingestion but also addressed the frequency of sexual intercourse and ED medication use.

Results: Of the 1458 respondents (response rate: 48%; median age: 48 years [interquartile range (IQR), 44-55]), 83% always/sometimes planned a specific time for intercourse in advance; 72% planned a specific time for sexual intercourse up to several hours in advance. Of respondents who planned in advance, more than half planned specific days of the week (55%) and times of the day (60%) for sexual intercourse. The time to sexual intercourse after dosing was ≤1 hour for 70% and ≤4 hours for 96% of men. The median frequency of sexual intercourse was 6 times/month (IQR, 4-10), with ED medication taken a median of 5 times/month (IQR, 3-8).

Conclusions: Sexual activity is usually planned by ED medication users several hours in advance, and the vast majority are attempting activity within a short time after ingestion of the agent. These data should aid clinicians in the selection of the optimal PDE5I.

Citing Articles

Phosphodiesterase type 5 inhibitors as treatment for erectile dysfunction: a webinar-based poll unveiling perceptions of healthcare professionals.

Moazin M, Baazeem A, Al-Bakri A, Al Dayel A, Amir A, Al Sifri S J Comp Eff Res. 2024; 13(7):e230155.

PMID: 38775343 PMC: 11225304. DOI: 10.57264/cer-2023-0155.

Real-World Assessment of the Impact of Erectile Dysfunction on Sexual Planning Behavior and Health- and Treatment-Related Outcomes Among Men in 8 Countries.

Goldstein I, Giraldi A, Maculaitis M, Li V, Hartzell-Cushanick R, Hassan T Sex Med. 2020; 8(3):338-349.

PMID: 32605816 PMC: 7471092. DOI: 10.1016/j.esxm.2020.05.001.

Challenges in the Practice of Sexual Medicine in the Time of COVID-19 in Japan.

Taniguchi H, Hisasue S, Sato Y J Sex Med. 2020; 17(7):1237-1238.

PMID: 32534861 PMC: 7266752. DOI: 10.1016/j.jsxm.2020.05.031.

The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue.

Zucchi A, Costantini E, Scroppo F, Silvani M, Kopa Z, Illiano E Andrology. 2019; 7(6):804-817.

PMID: 31350821 PMC: 6790582. DOI: 10.1111/andr.12683.

References

Boyle P, Robertson C, Mazzetta C, KEECH M, Hobbs R, Fourcade R . The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study. BJU Int. 2003; 92(7):719-25. DOI: 10.1046/j.1464-410x.2003.04459.x. View

Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E . The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res. 2001; 13(4):192-9. DOI: 10.1038/sj.ijir.3900713. View

Althof S, OLeary M, Cappelleri J, Hvidsten K, Stecher V, Glina S . Sildenafil citrate improves self-esteem, confidence, and relationships in men with erectile dysfunction: Results from an international, multi-center, double-blind, placebo-controlled trial. J Sex Med. 2006; 3(3):521-9. DOI: 10.1111/j.1743-6109.2006.00234.x. View

Goldstein I, Lue T, Padma-Nathan H, Rosen R, Steers W, Wicker P . Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med. 1998; 338(20):1397-404. DOI: 10.1056/NEJM199805143382001. View

Padma-Nathan H, McMurray J, Pullman W, Whitaker J, Saoud J, Ferguson K . On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res. 2001; 13(1):2-9. DOI: 10.1038/sj.ijir.3900631. View

Feldman H, Goldstein I, Hatzichristou D, Krane R, McKinlay J . Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994; 151(1):54-61. DOI: 10.1016/s0022-5347(17)34871-1. View

Hackett G, Kell P, Ralph D, Dean J, Price D, Speakman M . British Society for Sexual Medicine guidelines on the management of erectile dysfunction. J Sex Med. 2008; 5(8):1841-65. DOI: 10.1111/j.1743-6109.2008.00773.x. View

Eardley I, Dean J, Barnes T, Kirby M, Glasser D, Solanki J . The sexual habits of British men and women over 40 years old. BJU Int. 2004; 93(4):563-7. DOI: 10.1111/j.1464-410x.2003.04684.x. View

Nicolosi A, Moreira Jr E, Shirai M, Ismail Bin Mohd Tambi M, Glasser D . Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. Urology. 2003; 61(1):201-6. DOI: 10.1016/s0090-4295(02)02102-7. View

10.

Steidle C, McCullough A, Kaminetsky J, Crowley A, Siegel R, Deriesthal H . Early sildenafil dose optimization and personalized instruction improves the frequency, flexibility, and success of sexual intercourse in men with erectile dysfunction. Int J Impot Res. 2006; 19(2):154-60. DOI: 10.1038/sj.ijir.3901498. View

11.

Chen K, Chiang H, Jiann B, Lin J, Liu W, Wu C . Prevalence of erectile dysfunction and impacts on sexual activity and self-reported intercourse satisfaction in men older than 40 years in Taiwan. Int J Impot Res. 2004; 16(3):249-55. DOI: 10.1038/sj.ijir.3901218. View

12.

Koskimaki J, Hakama M, Huhtala H, Tammela T . Effect of erectile dysfunction on frequency of intercourse: a population based prevalence study in Finland. J Urol. 2000; 164(2):367-70. View

13.

. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA. 1993; 270(1):83-90. View

14.

Shaeer O, Shaeer K . The Global Online Sexuality Survey (GOSS): erectile dysfunction among Arabic-speaking internet users in the Middle East. J Sex Med. 2011; 8(8):2152-60. DOI: 10.1111/j.1743-6109.2011.02297.x. View

15.

Rosen R, Altwein J, Boyle P, Kirby R, Lukacs B, Meuleman E . Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003; 44(6):637-49. DOI: 10.1016/j.eururo.2003.08.015. View

16.

Riley A, Beardsworth A, Kontodimas S, Suarez D, Torres J, Haro J . Sexual intercourse frequency in men presenting for treatment of erectile dysfunction: results from the pan-European erectile dysfunction observational study. J Sex Marital Ther. 2006; 33(1):3-18. DOI: 10.1080/00926230600998417. View